Mode
Text Size
Log in / Sign up
Phase 4 N=116 Randomized Double-blind Other

Does Deep Neuromuscular Blockade Improve Operating Conditions During Total Hip Replacements?

Arthropathy of Hip

Enrolled (actual)
116
Serious AEs
0.0%
Results posted
Sep 2019
Primary outcome: Primary: Surgical Conditions — 1; 2; 11; 10 Participants

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Vecuronium 0.1 mg/kg (Drug); Vecuronium 0.2mg/kg (Drug)
Age
Adult, Older Adult · 50+ yrs
Sex
All
Sponsor
Craig Curry
Primary completion
Apr 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Surgical Conditions
1; 2; 11; 10; 30; 29
SECONDARY
Duration of Surgery
32.6; 33.8

Summary

During many surgeries, increased muscle tension makes it harder for the surgeon to expose the site of surgery and work within the incision. Neuromuscular blockade (NMB) drugs such as Vecuronium bind to neurotransmitter (acetyl choline) receptors at the neuromuscular junction, blocking their action and producing muscle relaxation. This muscle relaxation allows easier retraction of muscle tissues and manipulation of structures in the wound. Improved surgical conditions are likely to result in improved patient outcomes. While increased depths of NMB have been shown to optimize surgical conditions during intra-abdominal and retroperitoneal procedures, the impact of NMB depth has not been reported for orthopedic surgeries.1 To address this, we propose to study the effect of NMB depth on surgical conditions during total hip replacement (THR).

Eligibility Criteria

Inclusion Criteria

  • American Society of Anesthesiologists (ASA) Physical status 1-3
  • age 50-75
  • English speaking
  • able to provide informed consent
  • BMI equal to less than 30
  • non-emergent THR by anterolateral minimally invasive non-cemented total hip arthroplasty

Exclusion Criteria

  • Revision surgery
  • Bilateral THR
  • ASA 4+
  • age less than 50 or greater than 75
  • BMI greater than 30
  • unable to provide informed consent
  • women taking oral contraceptives (Sugammadex used for reversal interferes with their efficacy
  • contraindications to general inhalation anesthesia (such as malignant hyperthermia)
  • contraindications to NMB (known allergy to NMB)
  • chronic kidney disease
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03219294). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search